期刊文献+

Luminal亚型乳腺癌中临床病理因子间的关系 被引量:1

Relationship among Clinicopathological Factors in Luminal Subtype Breast Cancer
下载PDF
导出
摘要 目的:探讨Luminal亚型乳腺癌中临床病理因子间的关系。方法回顾性分析145例ER阳性乳腺癌的临床病理及免疫组织化学方法测定的分子生物学指标。结果按年龄将患者分为3组:40岁以下为青年组,40岁-59岁为中年组,60岁及以上为老年组。 T分期与N分期呈正相关,相关系数为0.272,P=0.001。 ER与PR表达强度间呈正相关,相关系数为0.469,P=0.000。年龄与HER2表达强度呈负相关,相关系数为-0.197,P=0.17。结论原发肿瘤越大腋窝淋巴结转移风险越高,ER和PR表达强度密切相关,年龄与HER2表达强度呈负相关,年龄越大,HER2表达强度越低。 Luminal亚型乳腺癌中PR、HER2是进一步分型和治疗选择的重要参考指标,准确检测至关重要。 Objective To explore relationship among clinicopathological factors in Luminal subtype breast cancer. Meth-ods The data of 145 female patients with Luminal subtype breast cancer were collected retrospectively. Their relationship with bi-omarkers, such as ER, PR, HER2, P53, age, stage of TNM was analyzed. Results Tumor size was positively related with me-tastasis of lymph node. The correlation between expression of ER and PR was statistically significant(r=0. 469, P=0. 000). The expression of HER2 was negatively related with age(r= -0. 197, P =0. 017). Conclusion The opportunity of metastasis of lymph node in large tumor is higher than in little tumor. The expression of ER and PR is coactions in breast cancer. The HER2 is more likely over expression in younger patient with breast cancer. PR and HER2 play important role in treatment of Luminal sub-type breast cancer, and need to be examined exactly.
出处 《四川医学》 CAS 2014年第4期448-449,共2页 Sichuan Medical Journal
关键词 Luminal亚型 乳腺癌 临床病理因子 luminal subtype breast cancer clinicopathological factors
  • 相关文献

参考文献6

  • 1Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implica- tions[ J]. Proc Nail Acad Sci USA, 2001, 98 (19) :10869-10874.
  • 2Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treat- ment of women with early breast cancer: highlights of the St Gallen In- ternational Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Annals of Oncology, 2013, 24(9) :2206-2223.
  • 3杨玲,李连弟,陈育德,D.M.Parkin.中国乳腺癌发病死亡趋势的估计与预测[J].中华肿瘤杂志,2006,28(6):438-440. 被引量:279
  • 4Tamoxifen for early breast cancer: an overview of the randomized tri- als. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials[ J]. Lancet, 1998, 351 (9114) :1451-1467.
  • 5Bardou VJ, Arpino G, Elledge RM, etal. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databas- es[J]. J Clin Oneol, 2003, 21(10) :1973-1979.
  • 6Xiong Q, Valero V, Kau V, etal. Female patients with breast carci- noma age 30 years and younger have a poor prognosis: the MD Ander- son Cancer Center experience [ J ]. Cancer, 2001, 92 ( 10 ) : 2523 -2528.

二级参考文献9

  • 1李连弟,鲁凤珠.1990—1992年中国恶性肿瘤死亡流行分布情况分析[J].中华肿瘤杂志,1996,18(6):403-407. 被引量:227
  • 2李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:869
  • 3全国肿瘤防治研究办公室 卫生部卫生统计信息中心.中国恶性肿瘤危险因素研究[M].北京:中国协和医科大学出版社,2003..
  • 4Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,2002. CA Cancer J Clin, 2005, 55:74-108.
  • 5Parkin DM, Whelan SL, Ferlay J, et al. Cancer in five continents.Vol Ⅷ. IARC scientific publication No. 155. Lyon: IARC Press,2002. 212-231.
  • 6Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med, 2000, 19 :335 -351.
  • 7Yang L, Parkin DM, Li LD, et al. Time trends in cancer mortality in China: 1987-1999. Int J Cancer, 2003, 106:771-783.
  • 8Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev, 2005, 14:243-250.
  • 9李连弟,张思维,鲁凤珠,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,夏毅,戴旭东,饶克勤,陈育德,孙爱明,薛志福.中国恶性肿瘤死亡谱及分类构成特征研究[J].中华肿瘤杂志,1997,19(5):323-328. 被引量:178

共引文献278

同被引文献5

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部